Destiny Pharma Share Discussion Threads

[jeanesy] 01/2/2024 08:17

looks like investors are deserting a sinking ship here !

[marvelman] 31/1/2024 17:58

I agree Arab :-))

[arab3] 31/1/2024 17:30

madness indeed
i think the saner heads were the ones selling at all the spikes !

[banshee] 31/1/2024 16:59

Let's hope there are no further similar issues to be unveiled, that would not go down well. They have been working with XF much longer than M3 and it's a very different beast, but a culture of non-professionalism (even if it is now historic), at a small bio will still make potential partners wary.

[controlledmadness] 31/1/2024 16:37

Looks like there is some panic selling. I assume its from those who do not understand pharmacutical companies.
But the buys are greater then the sells so it looks like saner heads think this is a good price to buy.

[henley2] 31/1/2024 16:26

Yes I know that, I can read too. But it’s obvious that the market would like some clarification from the company itself and some reassurance about XF73 nasal progress.

[brooko19] 31/1/2024 16:18

It clearly states in RNS any trials will be at the expense on Sebela

[waterloo01] 31/1/2024 16:18

Some people don't seem to read

[henley2] 31/1/2024 16:16

Well he could set out how long the delay is likely to be before P3 can start and how much if any it will cost Destiny.

[marvelman] 31/1/2024 16:09

I don't think there is anything else to explain now Henley..apart from XF73 nasal which is of course is the only one that really matters for now

[arab3] 31/1/2024 15:28

279p is he on drugs !

[marvelman] 31/1/2024 15:23

...but alas we won't be getting stage payments anytime soon it would seem

[edmonda] 31/1/2024 15:22

Clinical Development Updates - new research note with audio summary from Equity Development here:

Destiny Pharma has started the year with two important clinical development updates on its lead products which enhance both their profiles.

The clinical development update on XF-73 Dermal, which is a variation on Destiny’s XF-73 Nasal product included a preclinical study of an XF-73 Dermal formulation demonstrating that like XF-73 Nasal, it is also safe and applications to wounds results in negligible systemic levels.

On the non-toxigenic Clostridioides difficile strain M3, Destiny and partner Sebela Pharmaceuticals improved M3’s chemistry, manufacturing and controls program to incorporate a solid dose, rather than liquid formulation – which should improve patient compliance, manufacturing and storage costs – and changed the product’s contract manufacturer. While these changes may necessitate a bridging study between the two dosage forms, the costs all future M3 studies will be met by Destiny’s partner.

Our fair value remains unchanged at £245.7m, or 279 pence per share.

[barony] 31/1/2024 15:19

Can’t see anything -ve in this rns. In fact, it looks like the dermal product may be put to market earlier than anticipated. We wait for the nasal product, but any additional test costs are not down to us.

[arab3] 31/1/2024 15:11

not really, just looks like folk were spiked on the rumours of news that did not appear, that is what caused the last two rises

[jack jebb] 31/1/2024 15:03

"The stock market is a device for transferring money from the impatient to the patient.”

[waterloo01] 31/1/2024 14:48

Most likely as they state will need a phase 2/b on this partnered programe in C.diff However I don't think it has any bearing on the main product? Further the pre clinical work adds to the package, should one of the larger players decide to license


Destiny's priority remains to realise the maximum value for our XF-73 Nasal asset, given the substantial market potential of this product for Destiny Pharma and the significant potential benefits it presents for both patients and health systems. The Company is evaluating all options to achieve this, including continuing discussions with a number of potential partners, with a view to delivering the best deal to maximise shareholder value. We will provide a further update in due course.

Beyond XF-73 Nasal, Destiny looks forward to advancing the NTCD-M3 development programme through 2024, alongside its partner, Sebela Pharmaceuticals. Pre-clinical results are expected imminently for XF-73 Dermal and, in addition, the Company expects to make further progress across its XF drug platform and assets with target indications established for both XF-73 Dermal and XF-70, a novel anti-fungal from the XF drug platform, later in 2024.

[captain james t kirk] 31/1/2024 14:45

If Sebela decide to embark upon an additional phase 2 study before progressing to phase 3 there will be no cost to Destiny.
From today's rns :

"This may include a further Phase 2 study to de-risk Phase 3 study. As previously announced, Sebela has the right, at its own cost, to complete any further trials."

[john henry] 31/1/2024 14:31

Agree Banshee a change in the dose formulation will no doubt lead to a renewed phase 2 study.
How much funding will DEST be required to contribute to this new phase 2.
Phase 3 now looks at least 2 years away.

[banshee] 31/1/2024 14:12

Was there a previous mention of a repeat phase 2 for M3? Hard to say how likely that is exactly, but a distinct possibility, if only because if gives the pharma execs making the call cover from making a career damaging miscalculation. Like it or not that will add significant extra time if it happens, with all the associated bureaucracy, at least 12 months from the decision date and probably longer. It wouldn't enhance their reputation either.

[jack jebb] 31/1/2024 13:18

Many strings to this particular bow.

[gbjbaanb] 31/1/2024 13:01

This kind of stock is the kind that is manipulated. Look at the little bump up and then straight back down a while back, can't miss that on the charts. Almost like it was planned.

This is possibly the same, but in reverse. Market drops the price (perhaps making loads in shorts) and letting chums buy in. Ready for the next bump. And then repeat.

[marvelman] 31/1/2024 12:42

I get the impression that all the efforts are around an xf-73 deal and the rest is almost a side show in the bigger picture which will take time towards fruition. The fact that XF.73 nasal was not even mentioned is significant in itself in my opinion.